08/29/2026
Oh … wow. 🤯 Brain - gut connection?
The GLP-1 semaglutide is associated with a lower risk for psychiatric hospitalization and relapse in patients with bipolar disorder (BD) and diabetes and/or obesity. In a large observational study, semaglutide was associated with a 21% lower risk for psychiatric hospitalization and a 17% lower risk for hospitalization for BD relapse.
Neither liraglutide nor dulaglutide was associated with a significant reduction in psychiatric hospitalization, although the investigators noted that fewer users of these drugs may have limited the analyses. When GLP-1s were evaluated as a group, however, their use was associated with a lower hospitalization risk in this patient population.
The findings raise the possibility that these medications could eventually be used as an adjunct to mood stabilizers in patients with BD and obesity or type 2 diabetes, said study investigator Mark Taylor, MD, professor at School of Medicine and Dentistry, Griffith University, in Gold Coast, Australia, and a consultant psychiatrist. https://mdsc.pe/3SZCpnC